Global Cord Blood (CO) Competitors $1.06 +0.01 (+0.95%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CO vs. VMD, CORBF, QIPT, MRAI, BRTX, MGRX, OTRK, NIVF, FMS, and DVAShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Viemed Healthcare (VMD), Global Cord Blood (CORBF), Quipt Home Medical (QIPT), Marpai (MRAI), BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), Ontrak (OTRK), NewGenIvf Group (NIVF), Fresenius Medical Care (FMS), and DaVita (DVA). These companies are all part of the "miscellaneous health & allied services, not elsewhere classified" industry. Global Cord Blood vs. Viemed Healthcare Global Cord Blood Quipt Home Medical Marpai BioRestorative Therapies Mangoceuticals Ontrak NewGenIvf Group Fresenius Medical Care DaVita Global Cord Blood (NYSE:CO) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership. Do institutionals and insiders hold more shares of CO or VMD? 74.2% of Viemed Healthcare shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend CO or VMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viemed Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has more volatility & risk, CO or VMD? Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Does the media favor CO or VMD? In the previous week, Viemed Healthcare had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 4 mentions for Viemed Healthcare and 1 mentions for Global Cord Blood. Viemed Healthcare's average media sentiment score of 1.60 beat Global Cord Blood's score of 0.47 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Global Cord Blood 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viemed Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in CO or VMD? Global Cord Blood received 382 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 76.69% of users gave Global Cord Blood an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote. CompanyUnderperformOutperformGlobal Cord BloodOutperform Votes38576.69% Underperform Votes11723.31% Viemed HealthcareOutperform Votes342.86% Underperform Votes457.14% Which has stronger valuation and earnings, CO or VMD? Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$1.24B0.10$79.04M$0.641.66Viemed Healthcare$224.26M1.24$10.24M$0.2825.21 Is CO or VMD more profitable? Viemed Healthcare has a net margin of 4.87% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 8.72% beat Global Cord Blood's return on equity.Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A Viemed Healthcare 4.87%8.72%6.48% SummaryViemed Healthcare beats Global Cord Blood on 12 of the 17 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CO vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$128.84M$1.98B$5.54B$18.96BDividend YieldN/A7.12%5.09%4.01%P/E Ratio1.6615.9322.5732.87Price / Sales0.103.76399.8928.03Price / Cash4.199.3238.1817.52Price / Book0.173.986.774.47Net Income$79.04M$87.49M$3.22B$1.02B7 Day Performance0.95%-0.88%1.07%0.59%1 Month Performance11.58%-7.02%2.46%-3.54%1 Year PerformanceN/A-27.54%15.74%3.80% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGlobal Cord BloodN/A$1.06+1.0%N/AN/A$128.84M$1.24B1.661,202Analyst ForecastVMDViemed Healthcare1.7503 of 5 stars$7.07flatN/A-15.4%$279.42M$224.26M26.19630Upcoming EarningsShort Interest ↓Positive NewsCORBFGlobal Cord BloodN/A$1.05+10.5%N/AN/A$127.63M$196.12M0.001,200Gap UpQIPTQuipt Home Medical2.1381 of 5 stars$2.12+1.0%$6.25+194.8%-41.4%$91.35M$244.72M-12.47800Positive NewsMRAIMarpaiN/A$1.00flatN/A-50.2%$14.90M$34.87M-0.38150Upcoming EarningsGap UpBRTXBioRestorative Therapies3.9616 of 5 stars$1.70-0.6%$18.00+958.8%+29.9%$12.76M$401,000.00-1.117Short Interest ↓MGRXMangoceuticals0.9087 of 5 stars$1.78-1.7%N/A-97.3%$9.20M$615,873.00-0.313Short Interest ↓OTRKOntrak3.2351 of 5 stars$1.49+0.7%$45.00+2,920.1%-63.8%$6.29M$10.85M-0.14250NIVFNewGenIvf Group1.908 of 5 stars$0.31-11.6%N/A-99.1%$1.63M$5.14M0.00N/AGap DownFMSFresenius Medical Care3.8416 of 5 stars$25.05+2.4%$25.30+1.0%+18.0%$14.70B$19.34B20.70123,200Upcoming EarningsPositive NewsDVADaVita4.2827 of 5 stars$140.64+0.8%$166.33+18.3%+0.6%$11.25B$12.82B13.0970,000 Related Companies and Tools Related Companies VMD Competitors CORBF Competitors QIPT Competitors MRAI Competitors BRTX Competitors MGRX Competitors OTRK Competitors NIVF Competitors FMS Competitors DVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CO) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CO Stock Free CO Stock Alerts